ENTRY       D12014                      Drug
NAME        Sotrovimab (USAN/INN);
            Sotrovimab (genetical recombination) (JAN);
            Xevudy (TN)
FORMULA     C6492H10060N1744O2038S40
EXACT_MASS  146340.5997
MOL_WEIGHT  146430.4028
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYPFT SYGISWVRQA PGQGLEWMGW ISTYQGNTNY
            AQKFQGRVTM TTDTSTTTGY MELRRLRSDD TAVYYCARDY TRGAWFGESL IGGFDNWGQG
            TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
            PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 	NVNHKPSNTK VDKKVEPKSC
            DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
            GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
            GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
            DGSFFLYSKL TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
            (Light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQTVS STSLAWYQQK PGQAPRLLIY GASSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QHDTSLTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H154-H210, H230-L214, H236-H'236, H239-H'239, H271-H331, H377-H435, H'22-H'96, H'154-H'210, H'230-L'214, H'271-H'331, H'377-H'435, L23-L89, L134-L194, L'23-L'89, L'134-L'194)
  TYPE      Peptide
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
REMARK      Therapeutic category: 6250
            ATC code: J06BD05
            Product: D12014<JP>
EFFICACY    Antiviral
  DISEASE   COVID-19 [DS:H02398]
  TYPE      Monoclonal antibody
TARGET      SARS-CoV-2 spike glycoprotein [KO:K24152]
  PATHWAY   ko03230(K24152)  Viral genome structure
            ko05171(K24152)  Coronavirus disease - COVID-19
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J06 IMMUNE SERA AND IMMUNOGLOBULINS
               J06B IMMUNOGLOBULINS
                J06BD Antiviral monoclonal antibodies
                 J06BD05 Sotrovimab
                  D12014  Sotrovimab (USAN/INN) &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D12014  Sotrovimab (USAN/INN); Sotrovimab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12014  Sotrovimab
            Drug classes [BR:br08332]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12014  Sotrovimab
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               Coronavirus spike protein
                D12014  Sotrovimab (USAN/INN) &lt;JP&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12014
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12014
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12014
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12014
DBLINKS     CAS: 2423014-07-5
///
